The RADICAL Trial: Radium-223 Plus Cabozantinib in Bone Metastases From Kidney Cancer
In the Alliance A031801 (RADICAL) trial, adding radium-223 to cabozantinib did not improve skeletal event-free survival; the trial was stopped early for futility (Journal of Clinical Oncology, 2026).
- 6 DK OKUMA